Nkarta Q3 net loss $28.3M; cash $405.3M; drops NHL, focuses NKX019 on autoimmune

Nkarta, Inc.

2024-Q3 EPS reported -$1.26

Net loss of $28.3M ($0.39 per basic/diluted share) for Q3 2024; cash, equivalents, investments $405.3M.
First patient dosed in Ntrust-1 (lupus nephritis) and CUIMC IST (SLE); enrollment ongoing.
Ntrust-2 (systemic sclerosis, myositis, vasculitis) enrollment expected by year-end 2024; preliminary data in 2025.
Forgoes further NKX019 development in non-Hodgkin lymphoma; no new NHL trials planned.
Current cash expected to fund operations into late 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.